Literature DB >> 21070985

Immunohistochemistry of thymic epithelial tumors as a tool in translational research.

Mirella Marino1, Mauro Piantelli.   

Abstract

Due to their heterogeneity and infrequency, thymic epithelial cell tumors (TET) represent a diagnostic as well as a therapeutic problem. In the early stage of disease TET are usually cured by performing radical resections, whereas in advanced stages of disease they are usually radically unresectable from the beginning, and often show multiple relapses and/or intra- or extrathoracic metastases. Trained pathologists are required in TET diagnostics; awareness of the complexity of the mediastinum and of the differential diagnostic possibilities is mandatory. Immunohistochemical (IHC) studies play a fundamental role in oncologic surgical pathology. Among the many uses of IHC in cancer research, studies on a possible association between biomarker expression and treatment outcomes dominate the clinical translational research applications. This article reports on and discusses the role of IHC in diagnostic and translational research of TET.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21070985     DOI: 10.1016/j.thorsurg.2010.08.014

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  3 in total

Review 1.  Novel Agents in the Treatment of Thymic Malignancies.

Authors:  Claire Merveilleux du Vignaux; Jean-Michel Maury; Nicolas Girard
Journal:  Curr Treat Options Oncol       Date:  2017-08-10

Review 2.  Thymic malignancies: next-generation sequencing as a tool to select patients for targeted therapies and immunotherapies?

Authors:  Nicolas Girard
Journal:  Mediastinum       Date:  2019-09-26

Review 3.  Systemic treatments for thymic tumors: a narrative review.

Authors:  Paolo Andrea Zucali; Fabio De Vincenzo; Matteo Perrino; Nunzio Digiacomo; Nadia Cordua; Federica D'Antonio; Federica Borea; Armando Santoro
Journal:  Mediastinum       Date:  2021-09-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.